Jon Amund Kyte has combined expertise as clinical oncologist and immunotherapy researcher, and is Head of the Department for Experimental Cancer Therapy, and a Research Group Leader at Department for Cancer Immunology, Oslo University Hospital. The Department for Experimental Cancer Therapy includes the largest Early Phase Trial Unit in Norway, as well as a Clinical Trial Office and Study Nurse Unit, and currently conducts >70 clinical trials in oncology. Dr. Kyte has initiated three ongoing trials, ALICE, REPORT and ICON, combining immunological checkpoint inhibitors with chemotherapy or radiotherapy. The Kyte research group conducts translational research based on material from clinical trials, aimed at personalised cancer immunotherapy. Further, the group develops tumor-targeting chimeric antigen receptors (CARs) for T cell therapy against solid cancers, as well as strategies designed to make the CAR T cells resistant to immune suppression.